C9orf72 Motor Neurons

C9orf72 Motor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">C9orf72 Motor Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Specific Neurons</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Motor cortex (upper motor neurons), Spinal cord anterior horn (lower motor neurons)</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>Corticospinal motor neurons, Spinal motor neurons</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitter</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>C9orf72, TDP-43, Poly-GA, Poly-GP, Poly-GR</td>
</tr>
<tr>
<td class="label">Associated Gene</td>
<td>C9orf72 (Chromosome 9)</td>
</tr>
<tr>
<td class="label">Disease Association</td>
<td>ALS, FTD, ALS-FTD spectrum</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000100](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000100](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Repeat length</td>
<td>2-8</

C9orf72 Motor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">C9orf72 Motor Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Specific Neurons</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Motor cortex (upper motor neurons), Spinal cord anterior horn (lower motor neurons)</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>Corticospinal motor neurons, Spinal motor neurons</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitter</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>C9orf72, TDP-43, Poly-GA, Poly-GP, Poly-GR</td>
</tr>
<tr>
<td class="label">Associated Gene</td>
<td>C9orf72 (Chromosome 9)</td>
</tr>
<tr>
<td class="label">Disease Association</td>
<td>ALS, FTD, ALS-FTD spectrum</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000100](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000100](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Repeat length</td>
<td>2-8</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Penetrance</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">DPR Type</td>
<td>Properties</td>
</tr>
<tr>
<td class="label">Poly-GA</td>
<td>Most abundant</td>
</tr>
<tr>
<td class="label">Poly-GR</td>
<td>Arginine-rich</td>
</tr>
<tr>
<td class="label">Poly-PR</td>
<td>Arginine-rich</td>
</tr>
<tr>
<td class="label">Poly-GP</td>
<td>Less abundant</td>
</tr>
<tr>
<td class="label">Poly-GA</td>
<td>Forms inclusions</td>
</tr>
<tr>
<td class="label">Model Type</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">iPSC-derived motor neurons</td>
<td>Patient-specific, human</td>
</tr>
<tr>
<td class="label">iN cells</td>
<td>Rapid conversion</td>
</tr>
<tr>
<td class="label">Motor neuron spheroids</td>
<td>3D complexity</td>
</tr>
</table>

C9orf72 motor neurons are among the most affected neuronal populations in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), representing the most common genetic cause of these neurodegenerative diseases. The hexanucleotide repeat expansion in the C9orf72 gene (GGGGCC repeat) is responsible for approximately 40% of familial ALS cases and 25% of familial FTD cases [1](https://pubmed.ncbi.nlm.nih.gov/21944778/). This expansion leads to multiple pathological mechanisms including toxic RNA foci formation, dipeptide repeat (DPR) protein aggregation, and reduced C9orf72 protein expression, ultimately causing progressive motor neuron degeneration [2](https://pubmed.ncbi.nlm.nih.gov/22105375/). [@renton2011]

Overview

<!-- taxonomy-enrichment --> [@westergard2020]

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: motor neuron (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000100)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100)
• [OBO Foundry (CL:0000100)](http://purl.obolibrary.org/obo/CL_0000100)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000100)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100)
• [OBO Foundry (CL:0000100)](http://purl.obolibrary.org/obo/CL_0000100)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

Molecular Genetics

The C9orf72 Gene

The C9orf72 gene encodes a DENN domain protein involved in Rab GTPase regulation and autophagy [3](https://pubmed.ncbi.nlm.nih.gov/22031424/): [@ugwu2019]

• Gene structure: 12 exons spanning 7.4 kb
• Protein product: 481 amino acid protein with DENN domain
• Expression: Widely expressed in brain, particularly in pyramidal neurons and motor neurons
• Normal function: Regulates vesicular trafficking and autophagy

Hexanucleotide Repeat Expansion

The expansion occurs in the first intron of C9orf72, creating multiple pathogenic mechanisms [4](https://pubmed.ncbi.nlm.nih.gov/22131394/): [@xu2013]

Pathogenic Mechanisms

1. RNA Foci Formation

The expanded repeat is transcribed bidirectionally, generating sense and antisense RNA that forms nuclear RNA foci [5](https://pubmed.ncbi.nlm.nih.gov/22006339/): [@swaminathan2018]

• RNA foci sequester essential RNA-binding proteins
• Proteins sequestered include: TDP-43, FUS, hnRNPA1, hnRNPA2B1, ADARB1
• Leads to global RNA processing dysfunction
• Both sense and antisense foci contribute to pathogenesis

2. Dipeptide Repeat Protein (DPR) Toxicity

Five different DPRs are translated from the expansion (via repeat-associated non-ATG translation):

The poly-GR and poly-PR DPRs are particularly toxic to neurons [6](https://pubmed.ncbi.nlm.nih.gov/26220956/)

• Disrupt liquid-liquid phase separation (LLPS) of nuclear pores
• Impair nucleocytoplasmic transport
• Cause nucleolar stress
• Disrupt RNA granule dynamics

3. Loss of C9orf72 Function

The expansion leads to decreased C9orf72 expression through multiple mechanisms [7](https://pubmed.ncbi.nlm.nih.gov/25859385/):

• DNA methylation at the expansion site
• Reduced promoter activity
• Haploinsufficiency

• Autophagy initiation (regulates ULK1 complex)
• Lysosomal function
• Endosomal trafficking
• Inflammation (microglial function)

Role in ALS

Clinical Features

C9orf72-associated ALS presents with typical ALS features:

• Progressive muscle weakness (limb onset most common)
• Spasticity and hyperreflexia
• Bulbar symptoms (dysarthria, dysphagia)
• Respiratory involvement

• Earlier onset (~54 years) compared to sporadic ALS (~60 years)
• Higher likelihood of cognitive/behavioral impairment
• More pronounced executive dysfunction
• Higher prevalence of psychiatric symptoms

Neuropathology

C9orf72 motor neurons show characteristic pathological features:

• TDP-43 pathology: Neuronal cytoplasmic inclusions (NCI) in 100% of cases [8](https://pubmed.ncbi.nlm.nih.gov/22406069/)
• DPR inclusions: p62-positive, TDP-43-negative inclusions
• Neuronal loss: Marked loss of upper and lower motor neurons
• Gliosis: Prominent astrogliosis and microgliosis
• Bunina bodies: Present in some cases

Role in Frontotemporal Dementia (FTD)

Clinical Presentations

C9orf72 is the most common genetic cause of FTD:

• Behavioral variant FTD (bvFTD): Most common presentation
• Primary progressive aphasia (PPA): Less common
• ALS-FTD: Significant overlap (50% of C9orf72 ALS patients meet FTD criteria)

Neuropathology

C9orf72-FTD shows distinctive features:

• Type B TDP-43 pathology: Moderate neuronal cytoplasmic inclusions
• DPR inclusions: Particularly in frontal and temporal cortices
• Cerebellar involvement: DPR pathology extends to cerebellar granule cells
• Motor neuron involvement: Subclinical in many FTD cases

Therapeutic Implications

Antisense Oligonucleotide (ASO) Therapy

ASOs represent the most promising disease-modifying approach:

Approaches

• Reduce all C9orf72 RNA transcripts
• Potentially decrease both RNA foci and DPRs
• Concerns about complete knock-down

• Preserve normal C9orf72 function
• More technically challenging
• Requires knowledge of specific repeat length

• Block repeat-associated non-ATG (RAN) translation
• Does not affect C9orf72 expression
• Most direct approach to DPR toxicity

Clinical Trials

• Wave Life Sciences (WVE-004): ASO targeting C9orf72 in clinical trials [12](https://clinicaltrials.gov/ct2/show/NCT04931862)
• Ionis Pharmaceuticals: Various ASO candidates in preclinical/clinical development

Small Molecule Approaches

Gene Therapy

• AAV vectors: Deliver therapeutic genes to motor neurons
• CRISPR base editing: Correct repeat expansion or modify expression
• Gene replacement: Deliver functional C9orf72

Biomarkers

Genetic Testing

• Standard testing: PCR-based repeat-primed assay
• Confirmatory: Southern blot for repeat sizing
• Genetic counseling: Essential due to adult-onset, heritable nature

Fluid Biomarkers

• CSF DPRs: Poly-GP detectable in CSF; biomarker for target engagement [17](https://pubmed.ncbi.nlm.nih.gov/27210742/)
• Neurofilament light chain (NfL): Elevated in presymptomatic carriers and patients [18](https://pubmed.ncbi.nlm.nih.gov/32342608/)
• TDP-43: Total and phosphorylated TDP-43 in CSF

Neuroimaging

• MRI: Cortical thinning in motor and frontal regions
• PET: Hypometabolism in frontal/temporal cortex
• MRS: Reduced N-acetylaspartate in motor cortex

Research Models

Cellular Models

Key findings from cellular models [19](https://pubmed.ncbi.nlm.nih.gov/25651773/):

• DPR toxicity confirmed in human neurons
• Nuclear pore dysfunction demonstrated
• RNA foci formation validated
• Therapeutic targets identified

Animal Models

• C9orf72 BAC mice: Model RNA foci and some DPR pathology [20](https://pubmed.ncbi.nlm.nih.gov/25015738/)
• Drosophila models: Rapid screening, DPR toxicity validation [21](https://pubmed.ncbi.nlm.nih.gov/24240257/)
• Zebrafish models: Developmental studies, motor axon pathology [22](https://pubmed.ncbi.nlm.nih.gov/25882447/)

Clinical Management

Symptomatic Treatment

• Riluzole: Modest survival benefit
• Edaravone: Slows functional decline
• Multidisciplinary care: Essential for quality of life
• Genetic counseling: For family members

Emerging Therapies

• ASO clinical trials: Enrollment ongoing
• Gene therapy trials: Expected in next 5 years
• Combination approaches: Targeting multiple mechanisms

Cross-Links to Related Pages

• [C9orf72 Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [C9orf72 Protein](/proteins/c9orf72-protein)
• [Amyotrophic Lateral SclerosisMechanisms](/mechanisms)
• [C9orf72 Dipeptide Repeat Proteins](/proteins/c9orf72-dipeptide-repeat-proteins)
• [Frontotemporal Dementia Mechanisms](/mechanisms)
• [ALS](/diseases/als-ftd-spectrum)
• [TDP](/cell-types/tdp43-proteinopathy)
• [Spinal Cord Ventral Horn Motor Neurons](/cell-types/spinal-cord-ventral-horn-motor-neurons)
• [Motor Cortex Pyramidal Neurons](/cell-types/motor-cortex-pyramidal)
• [Corticospinal Tract Neurons](/cell-types/neurons)
• [Bulbospinal Neurons](/cell-types/neurons)

Background

The study of C9Orf72 Motor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [ALS Association - C9orf72 Research](https://www.als.org/) - Patient resources and research funding
• [C9orf72 Foundation](https://www.c9orf72.org/) - Dedicated research organization
• [NEALS Consortium](https://www.neals.org/) - Clinical trials network
• [ClinicalTrials.gov](https://clinicaltrials.gov/) - Current C9orf72 trials
• [GeneReviews - C9orf72](https://www.ncbi.nlm.nih.gov/books/NBK305428/) - Clinical information